leadf
logo-loader
viewVisioneering Technologies

Visioneering Technologies seeing 'consistent, very strong growth' each quarter

Visioneering Technologies (ASX:VTI) executive director & CEO Stephen Snowdy speaks to Proactive Investors about the US-based medical device company's revolutionary Natural VUE multifocal contact lenses for children with myopia and adults with presbyopia.

The vertically integrated company has recently grown its sales team in the US, and now has a large accounts base to leverage increased revenues from. Earlier this year, Visioneering Technologies obtained approvals to market its existing products in Europe, and Australia and New Zealand. Those international launches will happen this year, whilst new product releases are slated for 2019.

Quick facts: Visioneering Technologies

Price: 0.033 AUD

ASX:VTI
Market: ASX
Market Cap: $31.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Orthocell 'in exciting regulatory phase' as it looks to drive its...

Orthocell Ltd's (ASX:OCC) Paul Anderson says the company's in an exciting regulatory phase having validated its technologies in the clinic and defining pathways to market through the US FDA process. ''We have some significant milestones ahead of us - we have an application within the FDA at the...

20 hours, 7 minutes ago

2 min read